ReviewExperimental neurology2013
Marijuana, endocannabinoids, and epilepsy: potential and challenges for improved therapeutic intervention.
Review in Experimental neurology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 78 citations in OpenAlex.
- Integrating endocannabinoid signaling, CCK interneurons, and hippocampal circuit dynamics in behaving animals.Neuron · 2025Review
- Traumatic Brain Injury Outcomes After Recreational Cannabis Use.Neuropsychiatric disease and treatment · 2024Article
- Article
- The Role of the Possible Receptors and Intracellular Pathways in Protective Effect of Exogenous Anandamide in Kindling Model of Epilepsy.Neurochemical research · 2022Article
- Curcumin, Resveratrol and Cannabidiol as Natural Key Prototypes in Drug Design for Neuroprotective Agents.Current neuropharmacology · 2022Review
- Cannabinoids in Audiogenic Seizures: From Neuronal Networks to Future Perspectives for Epilepsy Treatment.Frontiers in behavioral neuroscience · 2021Review
- Review
- Crosstalk between the MCellular signalling · 2020Review
- Review
- Cannabinoid Actions on Neural Stem Cells: Implications for Pathophysiology.Molecules (Basel, Switzerland) · 2019Review
- Proceedings of the Epilepsy Foundation's 2017 Cannabinoids in Epilepsy Therapy Workshop.Epilepsy & behavior : E&B · 2018Article
- Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?Journal of epilepsy research · 2017Review
- Spatial distribution of cannabinoid receptor type 1 (CB1) in normal canine central and peripheral nervous system.PloS one · 2017Article
- Protective Effects of Cannabidiol against Seizures and Neuronal Death in a Rat Model of Mesial Temporal Lobe Epilepsy.Frontiers in pharmacology · 2017Article
- Endocannabinoid control of glutamate NMDA receptors: the therapeutic potential and consequences of dysfunction.Oncotarget · 2016Review
- Dentate cannabinoid-sensitive interneurons undergo unique and selective strengthening of mutual synaptic inhibition in experimental epilepsy.Neurobiology of disease · 2016Article
- Plasticity of Hippocampal Excitatory-Inhibitory Balance: Missing the Synaptic Control in the Epileptic Brain.Neural plasticity · 2016Review
- Cellular Mechanisms of Action of Drug Abuse on Olfactory Neurons.International journal of environmental research and public health · 2015Review
- Weeding out bad waves: towards selective cannabinoid circuit control in epilepsy.Nature reviews. Neuroscience · 2015Review
- Cannabidiol: promise and pitfalls.Epilepsy currents · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Phytocannabinoids isolated from the cannabis plant have broad potential in medicine that has been well recognized for many centuries. It is presumed that these lipid soluble signaling molecules exert their effects in both the central and peripheral nervous system in large part through direct interaction with metabotropic cannabinoid receptors. These same receptors are also targeted by a variety of endogenous cannabinoids including 2-arachidonoyl glycerol and anandamide. Significant effort over the last decade has produced an enormous advance in our understanding of both the cellular and the synaptic physiology of endogenous lipid signaling systems. This increase in knowledge has left us better prepared to carefully evaluate the potential for both natural and synthetic cannabinoids in the treatment of a variety of neurological disorders. In the case of epilepsy, long standing interest in therapeutic approaches that target endogenous cannabinoid signaling systems are, for the most part, not well justified by available clinical data from human epileptics. Nevertheless, basic science experiments have clearly indicated a key role for endogenous cannabinoid signaling systems in moment to moment regulation of neuronal excitability. Further it has become clear that these systems can both alter and be altered by epileptiform activity in a wide range of in vitro and in vivo models of epilepsy. Collectively these observations suggest clear potential for effective therapeutic modulation of endogenous cannabinoid signaling systems in the treatment of human epilepsy, and in fact, further highlight key obstacles that would need to be addressed to reach that goal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.